MAPT and Mental deterioration: The model of dynamic AD biomarkers [26,142] captures the biomarker magnitude depending on the clinical AD stage and is based on the longitudinal measurement of (i) amyloid pathology (Aβ42 in CSF and PET Aβ imaging), (ii) tau pathology (P-tau and T-tau in CSF), (iii) synaptic dysfunction (FDG-PET and fMRI), (iv) brain structure and neurodegeneration (volumetric MRI), and (v) clinical parameters (cognitive decline and dementia).